SCHEMBL27052005

SCHEMBL27052005

CCc1c(Cl)cc2nc(N)sc2c1C(C)C

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.41
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
SCN4A P35499 1/20 0.38
CYP3A4 P08684 3/20 0.33
ALDH1A1 P00352 3/20 0.33
TP53 P04637 2/20 0.33
TSHR P16473 2/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPT P10636 1/20 0.31
DRD2 P14416 2/20 0.31
KCNH2 Q12809 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31
GAA P10253 1/20 0.30
HTT P42858 1/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
PGK1 P00558 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27052004 0.86 SMN1; SMN2 (0.46) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27051995 0.85 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27051978 0.84 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27051986 0.81 HSD17B10 (0.42) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27052002 0.78 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27052003 0.77 SMN1; SMN2 (0.39) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27052011 0.77 SMN1; SMN2 (0.39) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27051983 0.75 SMN1; SMN2 (0.41) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27051907 0.73 SMN1; SMN2 (0.43) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4
SCHEMBL27051960 0.72 SMN1; SMN2 (0.45) SMN1; SMN2RAB9ANPC1SCN4ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 US disclosed
US-20240025918-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025918-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS SMN1; SMN2 3857/4885RAB9A 63/4885NPC1 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.